Pharminent

5 trends shaping Alzheimer’s drug development

Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned. http://www.biopharmadive.com/news/alzheimers-disease-trends-drug-development-amyloid-biomarkers/447068/

Filed under: Alzheimer’s

Roche’s Ocrevus racks up more positive MS data in relapsing and primary progressive forms

The positive data for Roche’s Ocrevus keep on coming. Friday, the company’s Genentech unit announced that the multiple-sclerosis fighter had significantly cut down disease activity and disability progression in patients with relapsing forms of the disease and those with the harder-to-treat, primary progressive forms. http://www.fiercepharma.com/marketing/roche-s-ocrevus-racks-up-more-positive-ms-data-relapsing-and-primary-progressive-forms

Filed under: MS

Alzheon says data backs potential of Alzheimer’s candidate

US biotech points to new analysis of phase III results for tramiprosate http://www.pmlive.com/pharma_news/alzheon_says_data_backs_potential_of_alzheimers_candidate_1196981

Filed under: Alzheimer’s

Merck licenses Teijin Pharma’s Alzheimer’s candidate

Merck has signed a worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. http://drugdiscovery.pharmaceutical-business-review.com/news/merck-tejin-sign-license-agreement-for-tau-targeting-antibody-260517-5825579

Filed under: Alzheimer’s

Celgene’s Data Could Lead To New Option For Multiple Sclerosis Patients

Celgene reported Monday that an experimental pill for the main type of multiple sclerosis met its main goals in a two-year study. By the end of the year, the Summit, NJ, drugmaker will ask the FDA to consider the drug, ozanimod, for approval. The Celgene (NASDAQ: CELG) drug is being tested in patients with relapsing […] http://www.xconomy.com/new-york/2017/05/22/celgenes-data-could-lead-to-new-option-for-multiple-sclerosis-patients/

Filed under: MS

Alzheimer’s experts call for changes in FDA drug approval standards

Leading Alzheimer’s disease researchers and a prominent patient advocate today published an analysis, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease," urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer’s disease. http://www.worldpharmanews.com/development/3931-alzheimer-s-experts-call-for-changes-in-fda-drug-approval-standards

Filed under: Alzheimer’s

Cytox Plans US Clinical Launch for Early-Stage Alzheimer’s Test While Courting Pharma Partners

https://www.genomeweb.com/molecular-diagnostics/cytox-plans-us-clinical-launch-early-stage-alzheimers-test-while-courting

Filed under: Alzheimer’s

Novartis real-world data confirms benefit of Gilenya in relapsing MS

https://www.europeanpharmaceuticalreview.com/50978/news/industry-news/novartis-real-world-data/

Filed under: MS

Breakthrough multiple sclerosis research sheds light on cause of the disease

Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.
read more http://www.pharmafile.com/news/513890/breakthrough-multiple-sclerosis-research-sheds-light-cause-disease

Filed under: MS

FDA authorizes first direct-to-consumer genetic test panel for predisposition to Alzheimer’s disease and other serious disorders

The FDA has announced its decision to grant a de novo application submitted by 23andMe for the company’s direct-to-consumer (DTC) Personal Genome Service Genetic Health Risk (“GHR") tests. The GHR test panel currently includes genetic variants…By: DLA Piper http://www.jdsupra.com/legalnews/fda-authorizes-first-direct-to-consumer-40610/

Filed under: Alzheimer’s

Genentech plans second Phase 3 Alzheimer’s trial following endpoint failures

Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody for the treatment of early Alzheimer’s disease.
The trial is designed to further elucidate earlier traces data on the drug’s efficacy in treating Alzheimer’s; crenezumab failed to meet its primary endpoint of slowing cognitive degeneration in mild-to-moderate forms of the disease in two 2014 Phase 2 studies, but did show promise as a treatment in the earliest stages.
read more http://www.pharmafile.com/news/513609/genentech-plans-second-phase-3-alzheimers-trial-following-endpoint-failures

Filed under: Alzheimer’s

NICE reverses decision on medication for relapsing multiple sclerosis

The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away from the headlines, the body continues to perform its role of determining which medicines will be available to patients. In this case, it has approved Biogen’s Zinbryta for patients suffering from relapsing remitting multiple sclerosis, though with the caveat of there being particular circumstances dependent for its use.
read more http://www.pharmafile.com/news/513589/nice-reverses-decision-medication-relapsing-multiple-sclerosis

Filed under: MS

Roche to start new trial of AC Immune drug against Alzheimer’s

http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/roche-start-trial-ac-immune-081559986.html

Filed under: Alzheimer’s

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

https://www.thestreet.com/story/14006548/1/celgene-multiple-sclerosis-pill-succeeds-in-first-late-stage-clinical-trial.html

Filed under: MS

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing
antibody in rare condition PSP, for which FDA has awarded
fast-track designation http://www.pmlive.com/pharma_news/abbvie_takes_anti-tau_drug_into_phase_ii_for_alzheimers_1185122

Filed under: Alzheimer’s

FDA extends review of Genentech’s application for multiple sclerosis drug OCREVUS

The US Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) date for review of Genentech’s Biologics License Application (BLA) for OCREVUS (ocrelizumab) to March 28, 2017. http://processandproduction.pharmaceutical-business-review.com/news/fda-extends-bla-review-of-genentechs-ocrevus-211216-5702612

Filed under: MS

Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer’s Disease

INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment for… http://www.prnewswire.com/news-releases/lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-treatment-for-alzheimers-disease-300375924.html

Filed under: Alzheimer’s

Amyloid Also Accumulates In Heart In Alzheimer’s (CME/CE)

(MedPage Today) — Small study shows heart function affected, too http://www.medpagetoday.com/Cardiology/CHF/61708

Filed under: Alzheimer’s

Roche confident in Alzheimer’s programmes, despite Lilly flop

http://finance.yahoo.com/news/roche-confident-alzheimers-programmes-despite-203033118.html

Filed under: Alzheimer’s

Study Challenges Model of Alzheimer’s Disease Progression

NewsAlzheimer’s disease is a neurodegenerative disorder for which, despite years of research, there are no effective treatments or cures.Contributed Author: Cornell UniversityTopics: Disease Research http://www.dddmag.com/news/2016/11/study-challenges-model-alzheimers-disease-progression

Filed under: Alzheimer’s

Categories